We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $111M
1-Year Est. Return 74.4%
This Fund
S&P 500
This Quarter Est. Return
+0.11%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$709M
AUM Growth
+$195M
Cap. Flow
+$27.5M
Cap. Flow %
3.88%
Top 10 Hldgs %
69.09%
Holding
206
New
48
Increased
50
Reduced
50
Closed
43

Top Buys

Rank Stock Value
1
ATER icon
Aterian
ATER
+$8.44M
2
COCP icon
Cocrystal Pharma
COCP
+$7.74M
3
RCON icon
Recon Technology
RCON
+$7.51M
4
LNAI
Lunai Bioworks
LNAI
+$5.46M
5
KRBP
Kiromic BioPharma, Inc. Common Stock
KRBP
+$4.18M

Top Sells

Rank Stock Value
1
VANI icon
Vivani Medical
VANI
+$4.81M
2
PENN icon
PENN Entertainment
PENN
+$4.24M
3
VTSI icon
VirTra
VTSI
+$3.45M
4
ASXC
Asensus Surgical, Inc.
ASXC
+$3.42M
5
RVPH
REVIVA PHARMA HLDGS INC
RVPH
+$2.4M

Sector Composition

Rank Sector Weight
1 Miscellaneous 81.19%
2 Healthcare 12.07%
3 Consumer Discretionary 1.47%
4 Financials 1.38%
5 Technology 1.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TRX icon
151
PUT
TRX Gold Corp
TRX
$393M
$80K 0.01%
1,568
+53
+3% +$29
NBRV
152
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$78K 0.01%
2,311
-4,249
-65% -$158K
BKYI
153
BIO-key International
BKYI
$3.84M
$65K 0.01%
94
-92
-49% -$60.5K
EVOK
154
DELISTED
Evoke Pharma
EVOK
$65K 0.01%
+329
New +$70.4K
TCDA
155
CALL
DELISTED
Tricida, Inc. Common Stock
TCDA
$63K 0.01%
+146
New +$696
ADMS
156
CALL
DELISTED
Adamas Pharmaceuticals
ADMS
$61K 0.01%
+553
New +$2.86K
ITP icon
157
PUT
IT Tech Packaging
ITP
$2.71M
$58K 0.01%
123
-145
-54% -$744
ODT
158
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$52K 0.01%
14,979
-619,749
-98% -$2.13M
NTBL
159
CALL
DELISTED
Notable Labs, Ltd. Ordinary Shares
NTBL
$47K 0.01%
+6
New +$455
GROMW
160
DELISTED
Grom Social Enterprises Inc. Warrants
GROMW
$29K ﹤0.01%
+982
New +$23.7K
ATHX
161
PUT
DELISTED
Athersys, Inc. Common Stock
ATHX
$29K ﹤0.01%
+8
New +$329
RYM
162
RYTHM Inc
RYM
$46.7M
– –
-7
Closed -$266K
ARKK icon
163
PUT
ARK Innovation ETF
ARKK
$6.44B
– –
-114
Closed -$1.37M
ATNM icon
164
PUT
Actinium Pharmaceuticals
ATNM
$39.3M
– –
-100
Closed -$76K
AUPH icon
165
Aurinia Pharmaceuticals
AUPH
$2.15B
– –
-85,625
Closed -$1.09M
BFLY icon
166
Butterfly Network
BFLY
$2.08B
– –
-33,047
Closed -$446K
BIIB icon
167
CALL
Biogen
BIIB
$31.9B
– –
-1,518
Closed -$42.5M
BIIB icon
168
PUT
Biogen
BIIB
$31.9B
– –
-100
Closed -$2.8M
CLGN icon
169
CollPlant Biotechnologies
CLGN
$6.43M
– –
-1,705
Closed -$229K
CRDF icon
170
CALL
Cardiff Oncology
CRDF
$104M
– –
-275
Closed -$255K
CRIS icon
171
CALL
Curis
CRIS
$2.74M
– –
-2
Closed -$912K
CTXR icon
172
Citius Pharmaceuticals
CTXR
$15.4M
– –
-12,560
Closed -$559K
KUST
173
CALL
Kustom Entertainment Inc
KUST
$3.78M
– –
0
– -$50K
GLD icon
174
CALL
SPDR Gold Trust
GLD
$145B
– –
-966
Closed -$15.5M
HEPA
175
DELISTED
Hepion Pharmaceuticals
HEPA
– –
-306
Closed -$560K
5 6
7
8 9

Similar funds

IWA
Independent Wealth Advisors Cary, North Carolina $111M AUM
BFA
Ballast Financial Advisors West Chester, Pennsylvania $110M AUM
WPWM
Western Pacific Wealth Management Lake Forest, Illinois $111M AUM 26.64% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return
ZS
Zenith Solutions Philadelphia, Pennsylvania $110M AUM
KC
Karras Company Roy, Utah $110M AUM
FI
FinArc Investments Norwood, Massachusetts $110M AUM
CIM
Catalyst Investment Management Windham, New Hampshire $110M AUM

Sabby Management's Q2 2021 Portfolio in Review

As of Q2 2021, Sabby Management held 206 positions worth $709M, up 38% from $514M the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Sabby Management deployed $27.5M of net new capital in Q2 2021, opening 48 new positions and adding to 50 existing holdings. Its largest new stake was Aterian: 36,083 shares worth $6.33M.

By sector, the portfolio is most concentrated in Miscellaneous at 81% of assets, up from 76% a quarter earlier, followed by Healthcare and Consumer Discretionary.

On the sell side, the largest reduction was Vivani Medical, an estimated $4.81M trimmed.

  • Sabby Management's largest Q2 2021 buy was Aterian: 36,083 shares worth $6.33M.
  • Sabby Management added most to Vincerx Pharma, Inc. Common Stock in Q2 2021, an estimated $2.87M increase.
  • Sabby Management's biggest Q2 2021 reduction was Vivani Medical, cutting an estimated $4.81M.
  • Sabby Management fully exited PENN Entertainment in Q2 2021, selling an estimated $4.24M.
  • Sabby Management's ten largest holdings make up 69% of its $709M portfolio in Q2 2021.
  • Sabby Management opened 48 new positions and closed 43 in Q2 2021.
  • Sabby Management's portfolio value rose 38% quarter-over-quarter to $709M.

Based on Sabby Management's 13F filing for Q2 2021, filed 16 Aug 2021.